Journal of Gastrointestinal Cancer

Multidisciplinary journal dedicated to understanding and treating cancers arising from the gastrointestinal tract. Publisher: @springernature. Editor: @jcloydmd

[Michael Shusterman, MD @guildsman]

GI Oncology standard regimen doses remain too high for many real world patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation are accumulating. #meded #gionc #crcsm #pancsm

[Julie Hallet @HalletJulie]

🚨#TOPGEAR ⚙️ results at #ESMO24

RCT: periop chemo w rads 🆚 no rads

👥 574 gastric/GEJ adenocarcinoma

⬆️ pCR with rads

❌ No difference in OS or PFS 🙅🏻‍♀️

That settles it then? 🤨

📝👇🏻

[JAMA Oncology @JAMAOnc]

Viewpoint by @dahaggstrom, @SigneBraafladt, and Paul K.J. Han describes the benefits and challenges of active surveillance as a clinical approach to monitor low-risk cancers with favorable prognoses. https://t.co/q0Ba0lezEs

[JAMA Surgery @JAMASurgery]

From @JAMA_current: Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications. https://t.co/mNvn9x8De2

[DCRjournal @DCRjournal]

Systematic review and meta-analysis of the effect of prehabilitation on LOS and functional capacity in pts undergoing resection for CRC. How much is LOS decreased? Read more in this month's #DCRJournal: https://t.co/eazTK0hZRD

@Swexner @me4_so @ACPGBI @drtracyhull @ASCRS_1

[Let's Win Pancreatic Cancer 💜 @letswinpc]

Welcome to #PancChat! Tonight we are chatting about #Nutrition and #PancreaticCancer.

[Syed A. Ahmad @SyedAAhmad5]

Laparoscopic versus open right hepatectomy for colorectal liver metastases after portal vein embolization: international multicentre study ⁦@BJSurgery⁩ https://t.co/6qSD87itTB

[JAMA Oncology @JAMAOnc]

Transarterial chemoembolization plus sorafenib for recurrent intermediate-stage hepatocellular carcinoma patients with microvascular invasion improved survival compared with transarterial chemoembolization alone. https://t.co/SGGUM82HtL

[Timothy M. Pawlik @timpawlik]

Check out this new paper by our @OhioStateSurg TEAM on guideline adherence to surveillance strategies in patients who underwent resection of #colorectal #cancer ▶️https://t.co/geVIkTjcgM #Colon #cancer @Zaibadawood @ZoraysM @YutakaEndoSurg @musaabmunir @LauraAlaimo5

[David James Pinato 🇺🇦 @DJPinato]

Local and systemic therapy in liver cancer: the quest for synergy @PinterMatthias @ImperialSandC @UniAvogadro https://t.co/UMmJ1BLwB2

[Olivia Sgarbura @oliviawriting]

Already thinking about this awesome congress next year: Venice mystery, great science, wonderful friends #PSOGI2023 @PSOGI_EC @ISSPP1

[JAMA Oncology @JAMAOnc]

The LASRE trial established the short-term oncologic safety of using laparoscopic surgery for low rectal cancer. The rate of complete total mesorectal excision was practically identical with laparoscopic surgery (85.3%) vs open surgery (85.8%). https://t.co/CTUZ0NULMG #Research

[JAMA Oncology @JAMAOnc]

Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. https://t.co/rCFntho0f1 #GICSM

[Arndt Vogel @ArndtVogel]

👉Upfront FOLFOXIRI plus Panitumumab does not improve outcome in #CRC now published in @JCO_ASCO
https://t.co/Cxsjgu1rzu

✅TRIPLETE phs-III, 88% left-sided tumors
👉relative "low" ORR, and more GI toxicity
❌more is not always better...

@myESMO @OncoAlert

[Harish K. Gagneja @hgagneja]

GI Subway map for you….@AmerGastroAssn @AmCollegeGastro @TexasGastros @AustinGastro @GI_Alliance @ASGEendoscopy #MedTwitter #GITwitter

[Journal of Clinical Oncology @JCO_ASCO]

🚀 LAUNCH trial demonstrates transarterial chemoembolization + lenvatinib improves survival for firstline therapy in patients with advanced #HepatocellularCarcinoma ➡️ https://t.co/zL60frzpfA #JCO #hpbcsm

[JAMA Oncology @JAMAOnc]

JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM

[Arndt Vogel @ArndtVogel]

🔥Global burden of cancer attributable to risk factor🔥
@TheLancet
https://t.co/UbFJJ0xbVr

🤔44% of global cancer deaths attributable to risk factors
🧐leading: smoking, alcohol, high BMI
👉Prevention, early diagnosis, effective therapy required

@myESMO @OncoAlert @EASLedu

[Timothy M. Pawlik @timpawlik]

Look 👀 what arrived in the mail today! Hot off the presses - our new book 📖 Edited by @AEjaz85 & myself, this book brings together 🌎🌏 experts to cover a broad range of topics on management of #colorectalcancer #metastatic #disease. Be sure to ✔️it out!

[Sabita Jiwnani @drsabita]

Does it matter if #esophagectomy is performed earlier in the week/closer to #weekend? Does the number & experience of OR/ICU personnel, logistics and infrastructure impact #postoperative outcomes? To find out, read our paper in @JournalGICancer @SpringerNature #GITwitter #surgery